Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Towards a hit for every target

Nature Reviews Drug Discovery volume 15, pages 1–2 (2016)Cite this article

Subjects

Abstract

Technological advances coupled with novel collaborative strategies for compound sourcing and management are poised to transform the utility of high-throughput screening.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Macarron, R. et al. Impact of high throughput screening in biomedical research. Nat. Rev. Drug. Discov. 10, 188–195 (2011).

    Article  CAS  Google Scholar 

  2. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014).

    Article  CAS  Google Scholar 

  3. Bakken, G. A. et al. Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy. J. Chem. Inf. Model. 52, 2937–2949 (2012).

    Article  CAS  Google Scholar 

  4. Simpson, P. B. & Reichman, M. Opening the lead generation toolbox. Nat. Rev. Drug Discov. 13, 3–4 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AstraZeneca, Cambridge Science Park, 310 Milton Road, Cambridge, CB4 0FZ, UK

    Steve Rees

  2. AstraZeneca, Cambridge Science Park, 310 Milton Road, Cambridge, CB4 0FZ, UK

    Garry Pairaudeau

  3. Fraunhofer Institute for Molecular Biology and Applied Ecology Ecology IME ScreeningPort, Schnackenburgallee 114, Hamburg, 22525, Germany

    Philip Gribbon

  4. AstraZeneca, 2 Kingdom Street, London, W2 6BD, UK

    Karen Birmingham

  5. Lead Discovery, Epizyme, 400 Technology Square, Cambridge, 02139, Massachusetts, USA

    William P. Janzen

Authors
  1. Steve Rees
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip Gribbon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen Birmingham
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William P. Janzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Garry Pairaudeau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steve Rees.

Ethics declarations

Competing interests

S.R, K.B. and G.P. are employees of AstraZeneca.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rees, S., Gribbon, P., Birmingham, K. et al. Towards a hit for every target. Nat Rev Drug Discov 15, 1–2 (2016). https://doi.org/10.1038/nrd.2015.19

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2015.19

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing